Abrocitinib Datasheet DC Chemicals

Description	Abrocitinib, also known as PF-04965842, is an oral Janus Kinase 1 inhibitor being investigated for treatment of plaque psoriasis. In January 2022, FDA approved abrocitinib for adults with moderate-to-severe atopic dermatitis. Abrocitinib at a dose of either 200 mg or 1 g once daily resulted in significantly greater reductions in signs and symptoms of moderate-to-severe atopic dermatitis than placebo at weeks 12 and 16. The 200-mg dose, but not the 100-mg dose, of abrocitinib was superior to dupilumab with respect to itch response at week 2.
Cat.No	DC75403
Name	Abrocitinib

Chemical Properties

CAS	1622902-68-4
Formula	C14H21N5O2S
MW	323.41
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

References

Return Policy

If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.

Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com